CXCR2 and leukemia: Previously, we found that TKI-treatment could activate a non-canonical NFKB2/Cytokines/Chemokines/CXCR2 pro-leukemia inflammatory pathway to initiate the survival and relapse of FLT3-mut AML blasts ex vivo (60).